Itch and atopic dermatitis: clinical and experimental studies

Area of Science:

• Dermatology
• Clinical Pharmacology
• Psychophysics

Background:

• Atopic dermatitis (AD) is characterized by intense pruritus, impacting patient quality of life.
• The precise mechanisms and quantitative measurement of itch in AD remain challenging.
• Understanding itch perception and treatment efficacy is crucial for managing AD.

Purpose of the Study:

• To develop and validate quantitative methods for measuring itch in AD.
• To investigate itch perception in AD patients compared to healthy controls.
• To evaluate the efficacy of H1-receptor antagonists and cyclosporin A in reducing itch in AD.

Main Methods:

• Development and testing of portable data-loggers (Pain-Track) and visual analogue scales (VAS) for itch measurement.
• Experimental induction of itch using histamine and wool fibers in healthy subjects and AD patients.
• Double-blind, randomized, placebo-controlled, cross-over studies evaluating antihistamines and cyclosporin A in AD patients.

Main Results:

• Both Pain-Track and VAS methods successfully quantified itch relief from topical corticosteroids.
• AD patients exhibited stronger itch responses to wool fibers but similar histamine dose-response curves compared to controls.
• Neither sedative nor non-sedative antihistamines showed significant itch relief compared to placebo, suggesting histamine is not the main pruritogen in AD.
• Cyclosporin A significantly reduced itch intensity, eczema scores, and eosinophil counts in AD patients.

Conclusions:

• Quantitative itch measurement tools, including Pain-Track, are effective for evaluating antipruritic treatments.
• Histamine may not be the primary driver of itch in atopic dermatitis.
• Cyclosporin A demonstrates significant efficacy in managing itch and skin inflammation in AD.